Mulberrin confers protection against hepatic fibrosis by Trim31/Nrf2 signaling

[1]  Jing Xu,et al.  Prediction of biochemical nonresolution in patients with chronic drug‐induced liver injury: A large multicenter study , 2021, Hepatology.

[2]  D. Hishikawa,et al.  Sphingosine‐1‐phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy , 2021, Hepatology.

[3]  Suwen Zhao,et al.  Conjugated secondary 12α-hydroxylated bile acids promote liver fibrogenesis , 2021, EBioMedicine.

[4]  Zhong-hua Wang,et al.  Maf1 Ameliorates Sepsis-Associated Encephalopathy by Suppressing the NF-kB/NLRP3 Inflammasome Signaling Pathway , 2020, Frontiers in Immunology.

[5]  D. Brenner,et al.  Molecular and cellular mechanisms of liver fibrosis and its regression , 2020, Nature Reviews Gastroenterology & Hepatology.

[6]  Yuwei Wang,et al.  TRIM31 inhibits NLRP3 inflammasome and pyroptosis of retinal pigment epithelial cells through ubiquitination of NLRP3 , 2020, Cell biology international.

[7]  Linfeng Hu,et al.  Nrf2 mitigates prolonged PM2.5 exposure-triggered liver inflammation by positively regulating SIKE activity: Protection by Juglanin , 2020, Redox biology.

[8]  Linfeng Hu,et al.  iRhom2 Promotes Hepatic Steatosis by Activating MAP3K7‐Dependent Pathway , 2020, Hepatology.

[9]  S. Muhammad,et al.  Role of NLRP3 inflammasome in liver diseases. , 2020, Journal of digestive diseases.

[10]  Haibo Xu,et al.  TNFAIP3 Interacting Protein 3 Overexpression Suppresses Nonalcoholic Steatohepatitis by Blocking TAK1 Activation. , 2020, Cell metabolism.

[11]  E. Crouchet,et al.  Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives , 2020, Cells.

[12]  Qiang Zhang,et al.  Hepatocyte-specific deficiency of Nrf2 exacerbates carbon tetrachloride-induced liver fibrosis via aggravated hepatocyte injury and subsequent inflammatory and fibrogenic responses. , 2020, Free radical biology & medicine.

[13]  Lungen Lu,et al.  Palmitic acid stimulates NLRP3 inflammasome activation through TLR4-NF-κB signal pathway in hepatic stellate cells , 2020, Annals of translational medicine.

[14]  Xiaolu Yang,et al.  TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway , 2020, Nature Communications.

[15]  J. Massagué,et al.  TGF-β orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1 , 2020, Nature.

[16]  Hongliang Li,et al.  Hepatocyte TNF Receptor–Associated Factor 6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lysine 6–Linked Polyubiquitination of Apoptosis Signal‐Regulating Kinase 1 , 2020, Hepatology.

[17]  Xiaolei Shi,et al.  Serum response factor (SRF) promotes ROS generation and hepatic stellate cell activation by epigenetically stimulating NCF1/2 transcription , 2019, Redox biology.

[18]  Weina Zhao,et al.  Mulberrin attenuates 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced Parkinson’s disease by promoting Wnt/β-catenin signaling pathway , 2019, Journal of Chemical Neuroanatomy.

[19]  Yongjie Ma,et al.  Loss of RIP3 initiates annihilation of high-fat diet initialized nonalcoholic hepatosteatosis: A mechanism involving Toll-like receptor 4 and oxidative stress. , 2019, Free radical biology & medicine.

[20]  Xiaopeng Wang,et al.  The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice , 2019, International immunopharmacology.

[21]  M. Pinzani,et al.  Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. , 2019, Molecular aspects of medicine.

[22]  S. Chauhan,et al.  TRIM16 employs NRF2, ubiquitin system and aggrephagy for safe disposal of stress-induced misfolded proteins , 2018, Cell stress.

[23]  Wei Zhang,et al.  Mulberrin (Mul) reduces spinal cord injury (SCI)-induced apoptosis, inflammation and oxidative stress in rats via miroRNA-337 by targeting Nrf-2. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[24]  K. Mortezaee.  Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) and liver fibrosis: A review , 2018, Cell biochemistry and function.

[25]  Katsunori Yoshida,et al.  Clinico-Pathological Importance of TGF-β/Phospho-Smad Signaling during Human Hepatic Fibrocarcinogenesis , 2018, Cancers.

[26]  Yuntao Guo,et al.  Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway , 2018, Theranostics.

[27]  Wen Liu,et al.  Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice , 2018, Cellular & Molecular Immunology.

[28]  D. Schuppan,et al.  Liver fibrosis: Direct antifibrotic agents and targeted therapies. , 2018, Matrix biology : journal of the International Society for Matrix Biology.

[29]  J. D. del Campo,et al.  Role of inflammatory response in liver diseases: Therapeutic strategies , 2018, World journal of hepatology.

[30]  Feng Li,et al.  The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis , 2018, Nature Medicine.

[31]  Y. Koyama,et al.  The role of human cytochrome P450 2E1 in liver inflammation and fibrosis , 2017, Hepatology communications.

[32]  Guoqing Zhang,et al.  Schisandrin B attenuates CCl4-induced liver fibrosis in rats by regulation of Nrf2-ARE and TGF-β/Smad signaling pathways , 2017, Drug design, development and therapy.

[33]  K. Schroder,et al.  NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. , 2017, Journal of hepatology.

[34]  Donggang Xu,et al.  Isobavachalcone Attenuates MPTP-Induced Parkinson's Disease in Mice by Inhibition of Microglial Activation through NF-κB Pathway , 2017, PloS one.

[35]  Y. Koyama,et al.  Liver inflammation and fibrosis. , 2017, The Journal of clinical investigation.

[36]  Jing Zhao,et al.  The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3 , 2016, Nature Communications.

[37]  G. Núñez,et al.  Mechanism and Regulation of NLRP3 Inflammasome Activation. , 2016, Trends in biochemical sciences.

[38]  Cheng Huang,et al.  Transmembrane protein 88 attenuates liver fibrosis by promoting apoptosis and reversion of activated hepatic stellate cells. , 2016, Molecular immunology.

[39]  F. Tacke,et al.  Liver fibrosis: Which mechanisms matter? , 2016, Clinical liver disease.

[40]  J. Cheng,et al.  MicroRNA-146a-5p Negatively Regulates Pro-Inflammatory Cytokine Secretion and Cell Activation in Lipopolysaccharide Stimulated Human Hepatic Stellate Cells through Inhibition of Toll-Like Receptor 4 Signaling Pathways , 2016, International journal of molecular sciences.

[41]  J. Cho,et al.  TRIM31 promotes Atg5/Atg7-independent autophagy in intestinal cells , 2016, Nature Communications.

[42]  D. Brenner,et al.  The Role of NADPH Oxidases (NOXs) in Liver Fibrosis and the Activation of Myofibroblasts , 2016, Front. Physiol..

[43]  Lei Zhang,et al.  TGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis , 2016, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[44]  D. Brenner,et al.  Deficiency of NOX1 or NOX4 Prevents Liver Inflammation and Fibrosis in Mice through Inhibition of Hepatic Stellate Cell Activation , 2015, PloS one.

[45]  I. Fabregat,et al.  Role of NADPH oxidases in the redox biology of liver fibrosis , 2015, Redox biology.

[46]  Chan-Min Liu,et al.  Protective effects of ursolic acid in an experimental model of liver fibrosis through Nrf2/ARE pathway. , 2015, Clinics and research in hepatology and gastroenterology.

[47]  P. Li,et al.  Inflammatory caspases are innate immune receptors for intracellular LPS , 2014, Nature.

[48]  S. Ki,et al.  Role of the Nrf2-ARE Pathway in Liver Diseases , 2013, Oxidative medicine and cellular longevity.

[49]  Zhu-ying Guo,et al.  Inhibitory effects of salvianolic acid B on CCl(4)-induced hepatic fibrosis through regulating NF-κB/IκBα signaling. , 2012, Journal of ethnopharmacology.

[50]  N. Chavez-Tapia,et al.  Role of oxidative stress and molecular changes in liver fibrosis: a review. , 2012, Current medicinal chemistry.

[51]  S. Yamada,et al.  Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models. , 2012, Journal of hepatology.

[52]  J. Fallowfield,et al.  Pathogenesis and treatment of hepatic fibrosis: is cirrhosis reversible? , 2011, Clinical medicine.

[53]  J. Boyer,et al.  Oxidative stress and hepatic stellate cell activation are key events in arsenic induced liver fibrosis in mice. , 2011, Toxicology and applied pharmacology.

[54]  L. V. van Grunsven,et al.  Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. , 2010, Journal of hepatology.

[55]  P. Muriel.  NF‐κB in liver diseases: a target for drug therapy , 2009, Journal of applied toxicology : JAT.

[56]  T. Sugiura,et al.  Characterization of TRIM31, upregulated in gastric adenocarcinoma, as a novel RBCC protein , 2008, Journal of cellular biochemistry.

[57]  A. Elsharkawy,et al.  Nuclear factor‐κB and the hepatic inflammation‐fibrosis‐cancer axis , 2007 .

[58]  S. Nisole,et al.  TRIM family proteins: retroviral restriction and antiviral defence , 2005, Nature Reviews Microbiology.

[59]  P. Olinga,et al.  Targeting Oxidative Stress for the Treatment of Liver Fibrosis. , 2018, Reviews of physiology, biochemistry and pharmacology.

[60]  B. Zhang,et al.  TRIM31 regulates chronic inflammation via NF-κB signal pathway to promote invasion and metastasis in colorectal cancer. , 2018, American journal of translational research.

[61]  N. Méndez-Sánchez,et al.  Management strategies for liver fibrosis. , 2017, Annals of hepatology.

[62]  D. Brenner.  Molecular pathogenesis of liver fibrosis. , 2009, Transactions of the American Clinical and Climatological Association.